Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T18:02:23.790Z.
Calculation as of: 2026-10-06T18:02:23.790Z.
Quote observation: 2026-10-06T18:00:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b98ba4015092d5f9d3a8f7230bb6a5b98cf1bb4c669b9b66f04bb37649ead8fd
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | $64.41M | N/A | N/A | N/A | N/A |
| RenovoRx, Inc. (RNXT)vs › | $64.43M | N/A | N/A | N/A | N/A |
| InterCure Ltd. (INCR)vs › | $63.14M | N/A | 14.25 | 33.42 | 30.04 |
| Heron Therapeutics, Inc. (HRTX)vs › | $63.92M | N/A | 2.96 | 2.96 | 2.96 |
| Alps Group Inc (ALPS)vs › | $63.25M | N/A | N/A | N/A | N/A |
| Pliant Therapeutics, Inc. (PLRX)vs › | $63.16M | N/A | 45.99 | 45.99 | 45.99 |
| Cingulate Inc. (CING)vs › | $66.20M | N/A | N/A | N/A | N/A |
| Fractyl Health, Inc. (GUTS)vs › | $61.54M | N/A | N/A | N/A | N/A |
| XBiotech Inc. (XBIT)vs › | $66.31M | N/A | 0.90 | 0.90 | 0.90 |
| iBio, Inc. (IBIO)vs › | $67.20M | N/A | 70.55 | 70.55 | 70.55 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$10.54
Forward EPS (Est.)
$-15.62
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
